Tibet Aim Pharm. (SZ:002826) Zheng Quan Shi Bao Wang·2025-06-09 11:39Group 1: Market Activity - 13 stocks had a closing order amount exceeding 100 million yuan, with the top four being Yiming Pharmaceutical (4.88 billion yuan), Zhongsheng Pharmaceutical (3.28 billion yuan), Jinying Co. (2.98 billion yuan), and Jianghuai Automobile (2.18 billion yuan) [3] - Yiming Pharmaceutical ranked first in closing order volume with 273,900 hands, followed by Zhongsheng Pharmaceutical and Yuheng Pharmaceutical, both exceeding 200,000 hands [2] Group 2: Company Announcements - Yiming Pharmaceutical announced that its actual controller, Gao Fan, signed a share transfer agreement to transfer 23% of the company's shares to Beijing Fuhai at a price of 15.1 yuan per share, totaling 662 million yuan [3] - The company reported revenues of 857 million yuan, 667 million yuan, and 652 million yuan for 2022, 2023, and 2024 respectively, with net profits of 44 million yuan, 15 million yuan, and 46 million yuan [3] Group 3: Sector Performance - The innovative drug sector saw several stocks hit the daily limit, including Changshan Pharmaceutical, Haichen Pharmaceutical, Shutaishen, and Ruizhizhi Pharmaceutical [4] - Haichen Pharmaceutical's main products include self-developed drugs that are selected in national drug procurement [4] Group 4: Investment Trends - The stocks with the highest net purchases on the Dragon and Tiger list included Changshan Pharmaceutical, Haichen Pharmaceutical, and Hahan Huatu, with net purchases exceeding 100 million yuan [8] - Institutions showed significant net buying in stocks like Kuaibao and Rejing Biological, while net selling was observed in Yuyin Co., Hengbao Co., and Xiongdi Technology [8]